Search results for Eli Lilly And Company

<![CDATA[Eli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeutics ]]>

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics]]>

<![CDATA[Eli Lilly Enters $ 2.3 Billion Agreement to Acquire Ajax Therapeutics ]]>

<![CDATA[Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio]]>

Eli Lilly to Acquire Kelonia Therapeutics

On April 20, 2026, Eli Lilly & Company (“Lilly”) and Kelonia Therapeutics, Inc. (“Kelonia”) announced an agreement for Lilly to acquire Kelonia in an all-cash transaction expec...

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio]]>

<![CDATA[Eli Lilly Enters Three Separate Acquisitions Totaling $3.83 Billion ]]>

Eli Lilly and Company 2026 Q1 - Results - Earnings Call Presentation

Here’s What the Street is Saying About Eli Lilly and Company (LLY)

Eli Lilly Just Got a Huge Vote of Confidence From Morgan Stanley -- and It's All About Mounjaro

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years

Eli Lilly & Co. CEO David Ricks on Tuesday said the company is investing heavily in artificial intelligence as well as follow-ons to its early weight-loss drugs.

StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod

Trung Huynh, an analyst with RBC Capital Markets, has projected Foundayo will reach peak-year sales of $36 billion—14% above the $31.68 billion racked up by last year’s best sellin...

<![CDATA[Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request ]]>

AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years

Eli Lilly & Co. CEO David Ricks announced the company is investing heavily in artificial intelligence and developing new weight-loss drugs to address side effects and help peop...

AI and GLP-1 drugs: Eli Lilly & Co.’s CEO talks of focus beyond 150 years

Eli Lilly & Co. CEO David Ricks announced the company is investing heavily in artificial intelligence and developing new weight-loss drugs to address side effects and help peop...

Lilly Dermatology Division?

Lilly Dermatology Division? Anonymous (not verified) Sun, 04/26/2026 - 11:14 field_thread_url https://cafepharma.com/boards/threads/lilly-dermatology-divis...

This Drug Stock Has Crushed the S&P 500 Over the Last Decade

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.

Lilly to buy startup Ajax in bid for a better JAK drug

Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.

Lilly Dermatology Division?

Lilly Dermatology Division? Anonymous (not verified) Tue, 04/21/2026 - 08:11 field_thread_url https://cafepharma.com/boards/threads/lilly-dermatology-divis...

Haryana drugs regulator reports fake Mounjaro seizure in Gurugram: Eli Lilly

Eli Lilly said it is extending support to the investigation into the seizure, reported to be worth ₹70 lakh

Barclays Sees Reinforced Long-Term Growth Narrative for Eli Lilly and Company (LLY)

Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch

A strong performance from Mounjaro overseas boosted Lilly’s results, and the company raised its guidance for the year for both profit and revenue.

CEO Of Lilly: It’s About Profits

CEO Of Lilly: It’s About Profits Anonymous (not verified) Thu, 04/02/2026 - 16:59 pharmagather item url CEO Of Lilly: It’s About Profits...

CVS obesity drug deal puts Lilly on equal footing with Novo

The agreement includes Lilly’s new pill Foundayo and restores coverage for Zepbound, erasing what had been a commercial edge for rival Novo Nordisk.